In January 2022, the EU formally approved a new indication for an oncological drug in metastatic colorectal cancer, for those patients who could not continue with their current treatment due to relevant and frequently seen side effects of their current treatment.
Following the support with the development of the EMA dossier, Meducom provided further medical content support for several local / national submissions of dossiers in three different European countries for the drug to seek reimbursement for this new indication.